{
  "meta": {
    "title": "Drugs_That_Act_In_Respiratory_System",
    "url": "https://brainandscalpel.vercel.app/drugs-that-act-in-respiratory-system-2f243451.html",
    "scrapedAt": "2025-11-30T11:19:46.843Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">Stimulates release of acetylcholine</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">Inhibits adenosine</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">Stimulates adenylyl cyclase</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">All of the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 34-year-old female presents to the OPD with complaints of cough and mild nocturnal dyspnea for the past 2 months. She reports that the symptoms worsen in cold weather. On examination, bilateral wheezing is noted over lung fields. Chest X-ray reveals increased lung fields bilaterally and a tubular-shaped heart. A diagnosis of bronchial asthma is made, and she is started on a combination of inhaled beta-2 agonist and corticosteroids. Beta-2 agonists improve symptoms of bronchial asthma primarily by which of the following mechanisms?</span></p>",
      "unique_key": "DT1176850",
      "question_audio": null,
      "question_video": null,
      "map_id": 1176850,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>&beta;2-adrenergic agonists</strong>, such as <strong>salbutamol</strong> or <strong>formoterol</strong>, are a mainstay in the treatment of <strong>bronchial asthma</strong> due to their <strong>bronchodilatory effect</strong>.</p>\n<ul>\n<li>These drugs act by <strong>stimulating &beta;2-adrenoceptors</strong> on bronchial smooth muscle.</li>\n<li>This <strong>activates adenylyl cyclase</strong>, leading to <strong>increased intracellular cyclic AMP (cAMP)</strong>.</li>\n<li>Elevated cAMP levels <strong>activate protein kinase A (PKA)</strong>, which <strong>inhibits myosin light-chain kinase</strong>, resulting in <strong>relaxation of bronchial smooth muscle</strong>.</li>\n<li>Additionally, &beta;2-agonists reduce the release of <strong>bronchoconstricting mediators</strong> from mast cells, <strong>reduce vascular permeability</strong>, and <strong>enhance mucociliary clearance</strong> by increasing ciliary activity.</li>\n</ul>\n<p>These actions make &beta;2-agonists effective for <strong>rapid symptom relief</strong> in asthma, particularly during <strong>nocturnal or exercise-induced bronchospasm</strong>.</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2024030846c4d6c2-7fab-4c36-a86e-e14ba8159033.jpg\">\n<p><strong>Side Effects of &beta;2-Agonists - \"3H, 3T\" Mnemonic:</strong></p>\n<p><strong>Due to increased cAMP levels</strong> (&beta;2-mediated):</p>\n<ul>\n<li><strong>H</strong>yperglycemia</li>\n<li><strong>H</strong>ypotension</li>\n<li><strong>T</strong>remor (most common side effect)</li>\n<li><strong>T</strong>achycardia</li>\n</ul>\n<p><strong>Other important adverse effects:</strong></p>\n<ul>\n<li><strong>H</strong>ypokalemia (due to intracellular shift of K+ mediated by &beta;2 stimulation)</li>\n<li><strong>T</strong>achyphylaxis/Tolerance (with prolonged use due to receptor desensitization)</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Stimulates release of acetylcholine (Option A):</strong></p>\n<p>Acetylcholine causes <strong>bronchoconstriction</strong> via muscarinic receptors. Beta-2 agonists do <strong>not</strong> stimulate its release; rather, anticholinergics block its effects.</p>\n<p><strong>Inhibits adenosine (Option B):</strong></p>\n<p><strong>Methylxanthines</strong> (e.g., theophylline), not beta agonists, inhibit adenosine. Adenosine causes bronchoconstriction.</p>",
      "correct_choice_id": 3,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">Indacaterol</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">Salbutamol</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">Salmeterol</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">All the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 65-year-old male presents to the emergency department with severe dyspnea. He refuses to lie down. Vital signs reveal SpO2 of 75% on room air, respiratory rate of 24/min, pulse rate of 124/min, and blood pressure of 130/86 mm Hg. Bilateral crepitations are heard on chest auscultation, and a chest X-ray reveals emphysematous changes. His relatives mention a history of chronic smoking. He is diagnosed with COPD. Which beta-agonist should be administered for management of this acute attack of dyspnea?</span></p>",
      "unique_key": "DT1176851",
      "question_audio": null,
      "question_video": null,
      "map_id": 1176851,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>In an <strong>acute exacerbation of COPD</strong>, <strong>short-acting beta-2 agonists (SABAs)</strong> are the <strong>first-line agents</strong> for rapid bronchodilation.</p>\n<ul>\n<li><strong>Salbutamol (Albuterol)</strong> is a <strong>short-acting &beta;<sub>2</sub>-agonist (SABA)</strong> that acts within minutes and is used as the <strong>drug of choice</strong> for <strong>immediate relief</strong> of dyspnea in acute COPD exacerbations. It improves airflow by relaxing bronchial smooth muscles.</li>\n<li><strong>Salmeterol</strong> and <strong>Indacaterol</strong> are <strong>long-acting beta-2 agonists (LABAs)</strong>:\n<ul>\n<li>Salmeterol is a twice-daily LABAsc.</li>\n<li>Indacaterol is an ultra-long-acting beta agonist, given once daily.</li>\n<li>Both are not suitable for acute relief and are instead used for <strong>maintenance therapy</strong> to reduce symptoms and prevent exacerbations.</li>\n</ul>\n</li>\n<li>For relief of <strong>acute symptoms</strong>, inhalation of a <strong>SABA (e.g., salbutamol)</strong>, a <strong>short-acting anticholinergic drug (e.g., ipratropium bromide)</strong>, or a <strong>combination of both</strong>, is usually effective and often used in emergency settings.</li>\n<li>For patients with <strong>persistent symptoms </strong>of exertional dyspnea and limitation of activities, regular use of <strong>long-acting bronchodilators,</strong> such as a <strong>LABA (e.g., salmeterol)</strong> or a <strong>long-acting anticholinergic (e.g., tiotropium)</strong> is recommended.</li>\n</ul>\n<p>In patients with <strong>severe airflow obstruction</strong> or <strong>frequent exacerbations</strong>, <strong>inhaled corticosteroids</strong> may be added to the regimen to reduce future flare-ups.</p>\n<p><strong>Key Takeaways:</strong></p>\n<ul>\n<li><strong>Salbutamol</strong> is the drug of choice for <strong>acute relief</strong> of dyspnea in COPD.</li>\n<li><strong>Salmeterol</strong> and <strong>Indacaterol</strong> are for <strong>long-term control</strong>, not acute use.</li>\n<li>Combined <strong>SABA + anticholinergic</strong> therapy improves acute bronchodilation.</li>\n</ul>",
      "correct_choice_id": 12,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">Inhibits the Phosphodiesterase enzyme</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">Inhibition of cell surface receptors for adenosine</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">Enhancement of histone deacetylation</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">All of the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 70-year-old male patient presents to the emergency department with severe dyspnea. He is a known case of COPD but has been non-compliant with medications. On room air, his SpO2 is 95%, pulse rate is 96/min, and BP is 126/80 mmHg. Clinical examination reveals clubbing in both hands, and coarse crepitations over lung fields. For symptom relief, he is administered intravenous aminophylline along with inhalational short-acting beta-agonist (SABA) and corticosteroids. What is the mechanism of action of aminophylline?</span></p>",
      "unique_key": "DT1176853",
      "question_audio": null,
      "question_video": null,
      "map_id": 1176853,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Aminophylline</strong>, a methylxanthine derivative, acts through <strong>multiple mechanisms</strong> to relieve bronchospasm and improve airflow in obstructive airway diseases like COPD and asthma:</p>\n<ul>\n<li><strong>Inhibition of phosphodiesterase (PDE) enzymes</strong>:</li>\n</ul>\n<p>Aminophylline inhibits PDE, particularly PDE3 and PDE4, which prevents breakdown of <strong>cyclic AMP (cAMP)</strong> and <strong>cyclic GMP (cGMP)</strong>. Elevated intracellular cAMP leads to <strong>bronchodilation</strong>, <strong>cardiac stimulation</strong>, and <strong>anti-inflammatory effects</strong>.</p>\n<ul>\n<li><strong>Antagonism of adenosine receptors</strong>:</li>\n</ul>\n<p>Aminophylline <strong>blocks adenosine receptors (A1 and A2A)</strong> on airway smooth muscle and mast cells. Adenosine normally causes <strong>bronchoconstriction</strong> and <strong>histamine release</strong>, especially in asthmatics, this antagonism contributes to bronchodilation.</p>\n<ul>\n<li><strong>Enhancement of histone deacetylation</strong>:</li>\n</ul>\n<p>Theophylline (active form of aminophylline) is thought to <strong>enhance histone deacetylase-2 (HDAC2)</strong> HDAC2 reverses histone acetylation, suppressing the expression of <strong>pro-inflammatory genes</strong>, thereby <strong>augmenting the anti-inflammatory effects</strong> of corticosteroids.</p>",
      "correct_choice_id": 24,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">Positive chronotropic, negative inotropic</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">Negative chronotropic, positive inotropic</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">Positive chronotropic and inotropic</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">Negative chronotropic and inotropic</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 70-year-old male patient presents to the OPD with complaints of cough, exertional dyspnea, and chest pain. On auscultation, bilateral rhonchi are heard over the lung fields, but no abnormal heart sounds or murmurs are detected. His pulse is 88/min and blood pressure is 116/78 mmHg. A chest X-ray is suggestive of COPD, and the patient is started on oral theophylline. What is the effect of theophylline on the cardiovascular system?</span></p>",
      "unique_key": "DT1176856",
      "question_audio": null,
      "question_video": null,
      "map_id": 1176856,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Theophylline</strong>, a <strong>methylxanthine derivative</strong>, is used as a bronchodilator in COPD and asthma. In the cardiovascular system, it exerts <strong>positive chronotropic</strong> (increased heart rate) and <strong>positive inotropic</strong> (increased myocardial contractility) effects.</p>\n<p>These effects occur due to:</p>\n<ul>\n<li><strong>Adenosine receptor antagonism</strong> at low concentrations: This <strong>inhibits presynaptic adenosine receptors</strong>, leading to <strong>increased catecholamine (e.g., norepinephrine)</strong> release from sympathetic nerve endings, enhancing cardiac stimulation.</li>\n<li><strong>Phosphodiesterase (PDE) inhibition</strong> at therapeutic levels (&gt;10 &micro;mol/L or ~2 mg/L): Increases intracellular cyclic AMP <strong>(cAMP)</strong> levels, which enhances <strong>calcium influx</strong>, promoting <strong>cardiac muscle contraction</strong>.</li>\n<li>At toxic levels (&gt;100 &micro;mol/L), there may be impaired <strong>calcium sequestration by the sarcoplasmic reticulum</strong>, potentially leading to arrhythmias or toxicity.</li>\n</ul>",
      "correct_choice_id": 33,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 3, 5</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 2, 4</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 3, 4</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 4, 5</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following sentences are true for methylxanthines?<br>1. They have positive chronotropic and inotropic effects on heart.<br>2. They inhibit the secretion of gastric acid and digestive enzymes.<br>3. They are weak diuretics but have no therapeutic significance.<br>4. They reverse fatigue of diaphragm in patient with COPD.<br>5. They cause bronchoconstriction.</span></p>",
      "unique_key": "DT1176857",
      "question_audio": null,
      "question_video": null,
      "map_id": 1176857,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Methylxanthines</strong> (notably <strong>theophylline</strong>) are bronchodilators with systemic effects, mediated by:</p>\n<ul>\n<li><strong>Phosphodiesterase (PDE) inhibition</strong> &rarr; &uarr; intracellular <strong>cAMP</strong></li>\n<li><strong>Adenosine receptor antagonism</strong></li>\n</ul>\n<p><strong>CVS effects:</strong></p>\n<ul>\n<li>Produce <strong>positive chronotropic and inotropic effects (Statement 1 is true)</strong></li>\n<li>At <strong>low concentrations</strong>, this results from <strong>adenosine receptor inhibition</strong>, increasing catecholamine release</li>\n<li>At <strong>higher concentrations</strong>, <strong>PDE inhibition</strong> leads to &uarr; cAMP and Ca2+ influx, enhancing myocardial contractility and heart rate</li>\n</ul>\n<p><strong>GIT effects:</strong></p>\n<ul>\n<li><strong>Stimulate</strong> gastric acid and <strong>digestive enzyme secretion</strong>, not inhibit <strong>(Statement 2 is false)</strong></li>\n<li>May lead to gastric irritation and risk of <strong>peptic ulceration</strong> in sensitive individuals</li>\n</ul>\n<p><strong>Renal effects:</strong></p>\n<ul>\n<li>Act as weak diuretics</li>\n<li>Mechanism: &uarr; <strong>glomerular filtration rate</strong> + &darr; <strong>tubular sodium reabsorption</strong></li>\n<li>However, the diuretic effect is <strong>minimal</strong> and has <strong>no therapeutic value (Statement 3 is true)</strong></li>\n</ul>\n<p><strong>Respiratory System:</strong></p>\n<ul>\n<li>Enhance <strong>skeletal muscle contractility</strong>, especially the <strong>diaphragm</strong></li>\n<li><strong>Reverse fatigue of respiratory muscles in COPD,</strong> improving ventilatory response to hypoxia and <strong>reducing dyspnea</strong> even in irreversible airway obstruction <strong>(Statement 4 is true)</strong></li>\n</ul>\n<p><strong>Airway Effect (Primary Therapeutic Action):</strong></p>\n<ul>\n<li><strong>Bronchodilation</strong>, not bronchoconstriction <strong>(Statement 5 is false)</strong></li>\n<li>Achieved by <strong>relaxation of airway smooth muscle</strong> and <strong>mast cell stabilization</strong></li>\n<li>No tolerance develops to this bronchodilatory action</li>\n</ul>",
      "correct_choice_id": 43,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">Both A and R are true, and R is the correct explanation of A</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">Both A and R are true, but R is not the correct explanation of A</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">A is true, but R is false</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">A is false, but R is true</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Assertion (A): Tiotropium does not inhibit M2 receptor-mediated auto-downregulation of acetylcholine release.<br>Reason (R): Tiotropium dissociates most rapidly from M2 receptors.<br>Which of the following is correct?</span></p>",
      "unique_key": "DT1176864",
      "question_audio": null,
      "question_video": null,
      "map_id": 1176864,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Tiotropium is a long-acting antimuscarinic agent <strong>(LAMA)</strong> used in the management of <strong>COPD</strong>.</p>\n<ul>\n<li>It binds with high affinity to <strong>M1, M2, and M3 muscarinic receptors</strong>, but its dissociation kinetics provide a functional selectivity.</li>\n<li>Specifically, <strong>tiotropium dissociates most rapidly from the M2 receptors</strong>, which are <strong>located presynaptically on parasympathetic nerves</strong> and are responsible for <strong>inhibiting acetylcholine release</strong> via negative feedback (auto-downregulation).</li>\n<li>Because tiotropium does <strong>not inhibit M2 receptor function</strong>, <strong>acetylcholine release is preserved</strong>, and excessive cholinergic stimulation is avoided. This preserved M2 function explains why tiotropium has a <strong>better safety and side effect profile</strong> than agents like ipratropium.</li>\n</ul>",
      "correct_choice_id": 51,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">Beta receptor agonist</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">Anti-fibrotic effect</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">Inhibition of infiltration of airway</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Suppression of mucus secretion</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 75-year-old male patient is a known case of COPD and is on combination therapy with a long-acting &beta;2 agonist (LABA) and corticosteroids. What is the most important action of corticosteroids in this context?</span></p>",
      "unique_key": "DT1176871",
      "question_audio": null,
      "question_video": null,
      "map_id": 1176871,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Corticosteroids are widely used in the <strong>management of COPD and asthma</strong> due to their potent <strong>anti-inflammatory properties</strong>.</p>\n<ul>\n<li>Their <strong>primary mechanism</strong> is the <strong>inhibition of inflammatory cell infiltration</strong> into the airway wall. This includes suppression of <strong>eosinophils</strong>, <strong>mast cells</strong>, and <strong>lymphocytes</strong>, which play a major role in chronic airway inflammation.</li>\n<li><strong>They do not act as direct bronchodilators</strong>, i.e., they <strong>do not activate &beta;2 receptors</strong>, although they can <strong>enhance the sensitivity and response to &beta;2 agonists</strong>, thereby offering a <strong>synergistic effect</strong> when used with LABAs. <strong>(Option A ruled out)</strong></li>\n<li>Although corticosteroids may exert some <strong>anti-fibrotic</strong> and <strong>mucus-suppressing</strong> effects, these are <strong>not the primary reason</strong> for their clinical use in obstructive airway disease.<strong> (Options B &amp; D ruled out)</strong></li>\n</ul>",
      "correct_choice_id": 63,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">0.5 mg/kg</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">1 mg/kg</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">1.5 mg/kg</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">2 mg/kg</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 78-year-old male presents to the emergency department with severe dyspnea. He is a known case of COPD and is on inhalational LABA + corticosteroids. His SpO2 on room air is 96%, pulse rate is 120/min, and blood pressure is 140/90 mm Hg. On auscultation, bilateral fine crepitations are heard. He needs urgent treatment for dyspnea. What is the appropriate dose of intravenous methylprednisolone every 6-12 hours?</span></p>",
      "unique_key": "DT1176874",
      "question_audio": null,
      "question_video": null,
      "map_id": 1176874,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>In cases of <strong>acute exacerbation of COPD</strong>, especially when patients present with <strong>increased dyspnoea</strong>, <strong>tachycardia</strong>, or auscultatory abnormalities (e.g., fine crepitations), <strong>systemic corticosteroids</strong> are a key component of initial management.</p>\n<ul>\n<li>For patients with <strong>moderate to severe dyspnea</strong>, or those who require hospitalization, <strong>intravenous corticosteroids</strong> are preferred.</li>\n<li>The recommended <strong>initial dose</strong> of IV <strong>methylprednisolone</strong> is <strong>1 mg/kg every 6 to 12 hours</strong> during the acute phase. This helps reduce airway inflammation, improve airflow, and accelerate recovery.</li>\n<li>Alternatively, <strong>oral prednisone</strong> can be started at <strong>30-60 mg per day</strong>, particularly when IV access is delayed or the patient is stable enough for oral administration.</li>\n<li>Once clinical improvement is noted, the corticosteroid dose is gradually <strong>tapered</strong> over 7-10 days.</li>\n<li>Prompt corticosteroid administration in acute exacerbation leads to <strong>faster improvement in lung function, reduced hospitalization duration, and decreased relapse rates</strong>.</li>\n</ul>",
      "correct_choice_id": 72,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">200 mcg/day</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">400 mcg/day</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">600 mcg/day</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">800 mcg/day</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Inhalational corticosteroids are preferred over oral prednisolone due to fewer systemic side effects. Which dose of inhalational beclomethasone is approximately equivalent to oral prednisone 10-15 mg/day?</span></p>",
      "unique_key": "DT1176876",
      "question_audio": null,
      "question_video": null,
      "map_id": 1176876,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Inhalational corticosteroids (ICS) are the <strong>mainstay of controller therapy in asthma</strong>, primarily because they allow for <strong>local delivery</strong> to the airways with <strong>minimal systemic absorption</strong>, thereby avoiding many of the systemic side effects seen with oral steroids.</p>\n<p><strong>Beclomethasone dipropionate</strong>, delivered via metered-dose inhaler, is a commonly used ICS.</p>\n<ul>\n<li>A total daily dose of <strong>400 mcg of inhaled beclomethasone</strong> (typically administered as <strong>two puffs twice daily</strong>) is considered <strong>therapeutically equivalent</strong> to <strong>oral prednisone 10-15 mg/day</strong> in terms of anti-inflammatory activity for asthma control.</li>\n<li>This dose achieves adequate airway anti-inflammatory effect <strong>without significant systemic effects</strong>, especially compared to systemic corticosteroids like oral prednisone.</li>\n</ul>\n<p>Other inhaled corticosteroids such as budesonide and fluticasone have similar efficacy but different potency and dosage equivalence.</p>",
      "correct_choice_id": 82,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">Salmeterol</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">Beclomethasone</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">Cromolyn</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">Montelukast</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following agents has no effect on airway smooth muscle tone and is ineffective in reversing asthmatic bronchospasm?</span></p>",
      "unique_key": "DT1176877",
      "question_audio": null,
      "question_video": null,
      "map_id": 1176877,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Cromolyn sodium (disodium cromoglycate)</strong> is a mast cell stabilizer that was once used in asthma management, especially in children, before being largely replaced by more effective treatments like inhaled corticosteroids and long-acting &beta;2-agonists.</p>\n<ul>\n<li><strong>Mechanism of Action:</strong> Cromolyn acts by <strong>inhibiting degranulation of mast cells</strong>, thereby preventing the release of histamine and other mediators involved in early and late-phase allergic responses.</li>\n<li><strong>Key Limitation:</strong> It <strong>does not relax airway smooth muscle</strong> and thus has <strong>no role in reversing acute bronchospasm</strong>. Its utility lies <strong>only in prophylaxis</strong>, particularly for <strong>exercise-induced</strong> or <strong>antigen-induced asthma</strong>, and requires regular dosing (usually 4 times daily) to reduce overall bronchial reactivity.</li>\n<li>Due to <strong>poor gastrointestinal absorption</strong>, it must be <strong>inhaled as a fine powder or aerosol suspension</strong>.</li>\n<li>While it can reduce the frequency of asthma attacks with regular use, <strong>it is ineffective in acute settings</strong>, where bronchodilators like &beta;2 agonists are preferred.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Salmeterol (Option A):</strong> A <strong>long-acting beta-2 agonist (LABA)</strong> that causes <strong>bronchodilation</strong> by directly acting on airway smooth muscle. Used in maintenance therapy of asthma (not for acute attacks), but <strong>has direct effect on smooth muscle tone</strong>.</p>\n<p><strong>Beclomethasone (Option B):</strong> An <strong>inhaled corticosteroid (ICS)</strong> that reduces <strong>airway inflammation</strong>. Although it does not directly cause bronchodilation, it <strong>reduces airway hyperreactivity over time</strong> and is effective in <strong>preventing asthma symptoms</strong>. Its role is <strong>anti-inflammatory</strong>, not smooth muscle relaxation.</p>\n<p><strong>Montelukast (Option D): </strong>A <strong>leukotriene receptor antagonist (LTRA)</strong> that blocks leukotriene-mediated effects such as <strong>bronchoconstriction and inflammation</strong>. It does not act directly on airway smooth muscle but <strong>reduces bronchospasm indirectly</strong> and is effective as an <strong>oral controller drug</strong>.</p>",
      "correct_choice_id": 93,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">Bacterial rhinoconjunctivitis</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">Viral rhinoconjunctivitis</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">Allergic rhinoconjunctivitis</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">All of the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Cromolyn and nedocromil are used as nasal sprays and eye drops to reduce symptoms of which of the following conditions?</span></p>",
      "unique_key": "DT1176879",
      "question_audio": null,
      "question_video": null,
      "map_id": 1176879,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Cromolyn sodium and nedocromil are <strong>mast cell stabilizers</strong> that inhibit the degranulation of sensitized mast cells, thereby preventing the release of inflammatory mediators like <strong>histamine and leukotrienes</strong>. These drugs are particularly useful in <strong>IgE-mediated hypersensitivity reactions</strong>, such as <strong>allergic rhinoconjunctivitis</strong>.</p>\n<ul>\n<li>When administered as a <strong>nasal spray or ophthalmic solution</strong>, they are effective in reducing symptoms like <strong>sneezing, nasal congestion, rhinorrhea, and conjunctival itching</strong> in allergic rhinoconjunctivitis, especially during pollen season.</li>\n<li>These agents are <strong>most effective when used prophylactically</strong> and require <strong>regular dosing (2-4 times daily)</strong>.</li>\n<li>Studies have shown efficacy in <strong>about 75% of patients</strong>, especially during high-allergen seasons like spring.</li>\n<li>They are <strong>not effective</strong> against infectious causes such as bacterial or viral conjunctivitis, since they act on allergic (immune-mediated) pathways, not infectious agents. <strong>(Options A, B &amp; D ruled out)</strong></li>\n</ul>\n<p>Though less potent than <strong>inhaled corticosteroids</strong>, they have the advantage of <strong>minimal systemic side effects</strong> and are commonly used in pediatric and mild allergic cases.</p>",
      "correct_choice_id": 103,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">4-lipoxygenase</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">5-lipoxygenase</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">6-lipoxygenase</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">7-lipoxygenase</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Leukotrienes are derived from arachidonic acid by the action of which enzyme?</span></p>",
      "unique_key": "DT1176882",
      "question_audio": null,
      "question_video": null,
      "map_id": 1176882,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Leukotrienes are <strong>inflammatory lipid mediators</strong> synthesized from <strong>arachidonic acid</strong> via the <strong>lipoxygenase pathway</strong>. The enzyme <strong>5-lipoxygenase</strong> is responsible for this conversion and is a <strong>key rate-limiting enzyme</strong> in leukotriene biosynthesis.</p>\n<ul>\n<li>This enzyme acts in <strong>inflammatory cells</strong> such as <strong>eosinophils, mast cells, basophils, and macrophages</strong>, playing a critical role in conditions like <strong>asthma and anaphylaxis</strong>.</li>\n<li><strong>Leukotriene B4 (LTB4)</strong> functions as a <strong>potent chemoattractant</strong> for neutrophils.</li>\n<li><strong>LTC4 and LTD4</strong> contribute to <strong>bronchoconstriction</strong>, <strong>mucosal edema</strong>, <strong>mucus hypersecretion</strong>, and <strong>airway hyperreactivity</strong>, all of which are hallmark features of <strong>asthma</strong> and other allergic conditions.</li>\n<li>Blocking leukotriene synthesis or receptor binding has been a major target in drug development, leading to agents like <strong>zileuton (5-lipoxygenase inhibitor)</strong> and <strong>montelukast (leukotriene receptor antagonist).</strong></li>\n</ul>",
      "correct_choice_id": 112,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">Inhibition of 5-lipoxygenase</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">LTD4 receptor antagonist</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">A and B both</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">LTB4 receptor agonist</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">What is the mechanism of action of leukotriene pathway inhibitors?</span></p>",
      "unique_key": "DT1176884",
      "question_audio": null,
      "question_video": null,
      "map_id": 1176884,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Leukotriene pathway inhibitors work through <strong>two primary mechanisms</strong> to counteract leukotriene-mediated inflammation, particularly in asthma and allergic conditions:</p>\n<ol>\n<li><strong>Inhibition of 5-lipoxygenase enzyme </strong>\n<ul>\n<li><strong>Zileuton</strong> is the prototype drug in this category.</li>\n<li>It inhibits the <strong>5-lipoxygenase enzyme</strong>, which converts arachidonic acid into leukotriene A4 (LTA4), thereby blocking the synthesis of downstream leukotrienes (including LTB4, LTC4, LTD4, and LTE4).</li>\n</ul>\n</li>\n<li><strong>Antagonism of the cysteinyl leukotriene receptor (specifically LTD4 receptor)</strong>\n<ul>\n<li><strong>Montelukast</strong>, <strong>zafirlukast</strong>, and <strong>pranlukast</strong> are selective antagonists of the <strong>CysLT1 receptor</strong>, which binds LTD4.</li>\n<li>This prevents bronchoconstriction, mucus production, and vascular permeability mediated by LTD4.</li>\n</ul>\n</li>\n</ol>\n<p>By either <strong>inhibiting leukotriene synthesis</strong> or <strong>blocking receptor-mediated actions</strong>, both mechanisms attenuate bronchoconstriction, mucus secretion, and inflammation in airway diseases. <strong>(Options A &amp; B ruled out)</strong></p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>LTB4 receptor agonist (Option D): </strong>LTB4 is a potent neutrophil chemoattractant. Agonism would <strong>exacerbate inflammation</strong>, not inhibit it. No therapeutic drugs use this pathway.</p>",
      "correct_choice_id": 123,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">10 mg once daily</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">10 mg twice daily</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">4 mg once daily</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">4 mg twice daily</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">What is the pediatric dose of montelukast?</span></p>",
      "unique_key": "DT1176890",
      "question_audio": null,
      "question_video": null,
      "map_id": 1176890,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Montelukast</strong> is a <strong>leukotriene receptor antagonist (LTRA)</strong> used for the prophylaxis and chronic treatment of asthma and allergic rhinitis.</p>\n<ul>\n<li>The <strong>standard pediatric dose</strong> of montelukast is <strong>4 mg once daily</strong>, typically used for children <strong>aged 2 to 5 years</strong>.</li>\n<li>For older children (6-14 years), the dose is <strong>5 mg once daily</strong>, and for adolescents and adults (&ge;15 years), <strong>10 mg once daily</strong> is the standard dose.</li>\n</ul>\n<p>Other leukotriene modifiers:</p>\n<ul>\n<li><strong>Zileuton</strong> (a 5-lipoxygenase inhibitor): 1200 mg twice daily (sustained-release)</li>\n<li><strong>Zafirlukast</strong>: 20 mg twice daily</li>\n</ul>",
      "correct_choice_id": 133,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">Tocilizumab</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">Itolizumab</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">Bevacizumab</span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">Omalizumab</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is an anti-IgE monoclonal antibody?</span></p>",
      "unique_key": "DT1176892",
      "question_audio": null,
      "question_video": null,
      "map_id": 1176892,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Omalizumab</strong> is a <strong>recombinant humanized monoclonal antibody</strong> that specifically targets <strong>immunoglobulin E (IgE)</strong>, a key mediator in the allergic cascade of asthma and other atopic conditions.</p>\n<ul>\n<li>It binds to the <strong>Fc region of free IgE</strong>, specifically the site that interacts with high-affinity IgE receptors (<strong>Fc&epsilon;RI and Fc&epsilon;RII</strong>) on <strong>mast cells and basophils</strong>, thereby <strong>preventing allergen-triggered degranulation</strong> and inflammatory mediator release.</li>\n<li>Importantly, it <strong>does not bind to IgE already attached to mast cells</strong>, avoiding receptor cross-linking and minimizing the risk of anaphylaxis.</li>\n</ul>\n<p>This makes Omalizumab a pivotal drug in the treatment of <strong>moderate to severe persistent allergic asthma</strong>, especially in patients with elevated IgE levels who are inadequately controlled with inhaled corticosteroids.</p>\n<p>Monoclonal antibodies used in asthma target different interleukins or receptors:</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250905da5a54ed-c848-4f42-9bd9-0d7f2c7936bd.png\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Tocilizumab (Option A):</strong> This is an <strong>anti-IL-6 receptor monoclonal antibody</strong>, used in <strong>rheumatoid arthritis</strong> and cytokine release syndromes, not in allergic asthma.</p>\n<p><strong>Itolizumab (Option B): </strong>This is a <strong>humanized anti-CD6 monoclonal antibody</strong>, used in <strong>psoriasis</strong> and <strong>COVID-19 cytokine storm</strong>, with no role in IgE-mediated conditions.</p>\n<p><strong>Bevacizumab (Option C): </strong>This monoclonal antibody targets <strong>VEGF (vascular endothelial growth factor)</strong> and is primarily used in <strong>cancers</strong> (e.g., colorectal, renal cell carcinoma) and <strong>ocular neovascular diseases</strong>.</p>",
      "correct_choice_id": 144,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16,
      "choices": [
        {
          "id": 151,
          "text": "<p><span style=\"font-size:12.0pt;\">50</span></p>"
        },
        {
          "id": 152,
          "text": "<p><span style=\"font-size:12.0pt;\">60</span></p>"
        },
        {
          "id": 153,
          "text": "<p><span style=\"font-size:12.0pt;\">80</span></p>"
        },
        {
          "id": 154,
          "text": "<p><span style=\"font-size:12.0pt;\">90</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Additional treatment with inhalational beta agonists is needed when FEV1 is less than ____ % of predicted.</span></p>",
      "unique_key": "DT1176894",
      "question_audio": null,
      "question_video": null,
      "map_id": 1176894,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Bronchial asthma</strong> management depends on the severity and frequency of symptoms, as well as objective measures of lung function, such as <strong>forced expiratory volume in 1 second (FEV1)</strong>.</p>\n<ul>\n<li>Patients with <strong>intermittent asthma</strong>, who experience symptoms <strong>less than twice a week</strong> and have <strong>normal FEV1 (&gt;80%)</strong>, usually require only <strong>as-needed inhaled &beta;2-agonists</strong> (e.g., albuterol).</li>\n<li>However, if:\n<ul>\n<li>Symptoms occur <strong>more than twice per week</strong>,</li>\n<li><strong>Nocturnal symptoms</strong> are present <strong>more than twice a month</strong>, or</li>\n<li><strong>FEV1 &lt; 80% of predicted</strong>, then <strong>additional maintenance therapy</strong> is warranted.</li>\n</ul>\n</li>\n<li>The <strong>first-line controller medication</strong> is a <strong>low-dose inhaled corticosteroid (ICS)</strong>. Alternatives include <strong>leukotriene receptor antagonists (LTRAs)</strong> or <strong>mast cell stabilizers</strong> like <strong>cromolyn</strong>.</li>\n<li><strong>Theophylline</strong> is now rarely used due to its narrow therapeutic window and side effect profile and is typically reserved for cases unresponsive to standard therapies.</li>\n</ul>",
      "correct_choice_id": 153,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17,
      "choices": [
        {
          "id": 161,
          "text": "<p><span style=\"font-size:12.0pt;\">Causes tachycardia</span></p>"
        },
        {
          "id": 162,
          "text": "<p><span style=\"font-size:12.0pt;\">Causes bradycardia</span></p>"
        },
        {
          "id": 163,
          "text": "<p><span style=\"font-size:12.0pt;\">Causes cardiac arrhythmias</span></p>"
        },
        {
          "id": 164,
          "text": "<p><span style=\"font-size:12.0pt;\">None of the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is false regarding Deriphylline?</span></p>",
      "unique_key": "DT1176898",
      "question_audio": null,
      "question_video": null,
      "map_id": 1176898,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Deriphylline</strong> is a combination of <strong>theophylline and etofylline</strong>, both of which belong to the <strong>methylxanthine class</strong> of drugs. These agents exhibit both <strong>bronchodilator</strong> and <strong>cardiostimulant</strong> effects.</p>\n<ul>\n<li>Methylxanthines have <strong>positive inotropic</strong> (increased contractility) and <strong>chronotropic</strong> (increased heart rate) effects.</li>\n<li><strong>Mechanism:</strong> At <strong>low concentrations</strong>, they block <strong>adenosine receptors</strong> on presynaptic sympathetic nerves, leading to <strong>increased catecholamine release</strong>, thereby stimulating the heart.</li>\n<li>At <strong>moderate to high concentrations</strong>, they <strong>inhibit phosphodiesterase</strong>, increasing <strong>cAMP</strong> levels, which enhances <strong>calcium influx</strong>, contributing to arrhythmogenic potential.</li>\n<li>At <strong>very high concentrations (&gt;100 &micro;mol/L)</strong>, <strong>calcium sequestration by the sarcoplasmic reticulum</strong> is impaired, further contributing to <strong>cardiac excitability and arrhythmias</strong>.</li>\n</ul>\n<p>Hence, <strong>tachycardia and cardiac arrhythmias</strong> are known adverse effects. <strong>Bradycardia</strong> is <strong>not</strong> typically associated with methylxanthine toxicity or therapeutic use</p>",
      "correct_choice_id": 162,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18,
      "choices": [
        {
          "id": 171,
          "text": "<p><span style=\"font-size:12.0pt;\">80</span></p>"
        },
        {
          "id": 172,
          "text": "<p><span style=\"font-size:12.0pt;\">70</span></p>"
        },
        {
          "id": 173,
          "text": "<p><span style=\"font-size:12.0pt;\">60</span></p>"
        },
        {
          "id": 174,
          "text": "<p><span style=\"font-size:12.0pt;\">50</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Initial treatment with oral and inhalational corticosteroids is recommended for patients with severe airway obstruction. Severe airway obstruction is defined as FEV1 less than what percentage of the predicted value?</span></p>",
      "unique_key": "DT1176899",
      "question_audio": null,
      "question_video": null,
      "map_id": 1176899,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>In the management of <strong>bronchial asthma</strong>, if symptoms are <strong>frequent or severe</strong>, or if there is <strong>significant airflow limitation despite bronchodilator therapy</strong>, <strong>inhaled corticosteroids (ICS)</strong> should be initiated.</p>\n<ul>\n<li>In cases. where <strong>FEV1 &lt; 50% of predicted</strong>, this is classified as <strong>severe airway obstruction</strong>, and treatment should include <strong>both inhaled and oral corticosteroids</strong>.</li>\n<li>A common regimen is <strong>prednisone 30 mg/day</strong> orally for approximately <strong>3 weeks</strong>, combined with ICS.</li>\n<li>Clinical improvement is generally observed within <strong>7-10 days</strong>, after which oral corticosteroids can be <strong>tapered or discontinued</strong>.</li>\n</ul>\n<p>Additionally, the <strong>GOLD (Global Initiative for Chronic Obstructive Lung Disease)</strong> classification stages the severity of COPD based on the <strong>post-bronchodilator FEV1 percentage of predicted value</strong>, with the <strong>mandatory criterion</strong> of FEV1/FVC &lt; 0.7.</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250906c8641b12-5d3c-40b6-a72c-cac032620d39.png\">",
      "correct_choice_id": 174,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19,
      "choices": [
        {
          "id": 181,
          "text": "<p><span style=\"font-size:12.0pt;\">Lymphocytic</span></p>"
        },
        {
          "id": 182,
          "text": "<p><span style=\"font-size:12.0pt;\">Eosinophilic</span></p>"
        },
        {
          "id": 183,
          "text": "<p><span style=\"font-size:12.0pt;\">A and B both</span></p>"
        },
        {
          "id": 184,
          "text": "<p><span style=\"font-size:12.0pt;\">Basophilic</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Omalizumab is used to reduce the frequency and severity of exacerbations by targeting which type(s) of inflammation?</span></p>",
      "unique_key": "DT1176900",
      "question_audio": null,
      "question_video": null,
      "map_id": 1176900,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Omalizumab</strong> is a recombinant <strong>humanized monoclonal antibody</strong> that targets <strong>IgE</strong>. It is indicated in patients with <strong>chronic moderate-to-severe allergic asthma</strong> who remain <strong>symptomatic despite high-dose inhaled corticosteroids and long-acting &beta;2-agonists</strong>.</p>\n<ul>\n<li>The drug acts by binding to the <strong>Fc portion of free IgE</strong>, preventing it from attaching to mast cells and basophils.</li>\n<li>This reduces the <strong>release of proinflammatory mediators</strong>, ultimately leading to <strong>downregulation of allergic inflammation</strong>.</li>\n</ul>\n<p>Omalizumab has been shown to reduce:</p>\n<ul>\n<li><strong>Lymphocytic inflammation</strong>, particularly <strong>Th2 cells</strong>, which drive allergic responses.</li>\n<li><strong>Eosinophilic inflammation</strong>, which contributes significantly to airway hyperresponsiveness and late-phase allergic reactions. <strong>(Options A &amp; B ruled out)</strong></li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Basophilic (Option D):</strong></p>\n<p>Omalizumab binds to <strong>circulating IgE</strong> and prevents mast cell and basophil activation but <strong>does not directly reduce basophilic inflammation</strong> in the bronchial mucosa.</p>",
      "correct_choice_id": 183,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}